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Abstract. There are now a number of potential candi-
dates for inherited thrombophilia but a definite causal
relationship has been established for only a proportion
of these. Accepted causes of familial thrombophilia
include the factor V Leiden defect and the prothrombin
20210 G>A variant, äs well äs deficiencies of
antithrombin, protein C and protein S. Together these
inherited abnormalities account for 30-50% of indi-
viduals presenting with venous thromboembolism.
Factor V Leiden, which is present in up to 7% of the
European population, is the most common cause of
familial thrombophilia. On a worldwide basis its preva-
lence varies greatly with ethnic origin. In common
with other types of familial thrombophilia the fre-
quency of factor V Leiden is highly dependent on the
population group studied. Venous thromboembolism,
present in approximately 55% of individuals with
familial coagulation Inhibitor deficiencies, is the pre-
dominant clinical manifestation of familial throm-
bophilia. There are indications that the venous
thrombotic risk is somewhat less in those with factor V
Leiden. The thrombotic risk is markedly increased in
those with combined defects and in those who are
homozygous for factor V Leiden. Risk factors for throm-
bosis include pregnancy, including the puerperium,
surgery, oral contraceptive usage and prolonged peri-
ods of immobilization. A substantial proportion of
venous thrombotic events may occur spontaneously,
i.e. without an obvious precipitating event. The man-
agement of patients with familial thrombophilia
comprises counselling, thromboprophylaxis and
thrombosis treatment. Although the immediate
treatment of an acute thrombotic event is not signifi-
cantly different from that of patients without recog-
nised abnormalities, detailed patient management is
seriously hampered by a lack of appropriate clinical
trials. Prospective clinical studies, designed to ascertain
individual thrombotic risk and to evaluate different
therapeutic strategies are urgently required.
Keywords: thrombophilia, venous thrombosis, risk
factors, management.
Introduction
The coagulation System is essentially a series of linked
reactions involving zymogens, their respective serine
proteases and cofactors. The System is controlled
through a series of feedback mechanisms and by the
action of inhibitors. The functions of the coagulation
system are closely linked to those of the fibrinolytic
System with fibrin being the natural Substrate for the
fibrinolytic enzyme, plasmin.
It is only in recent years that the physiological and
clinical importance of blood coagulation inhibitors
has become appreciated. Although antithrombin III
deficiency was first described in 1965, it was not until
the 1980s, following the first reports of familial defi-
ciencies of protein C and protein S that coagulation
inhibitors became generally recognized äs being at
least äs important äs procoagulants in the pathogen-
esis of venous thromboembolism.
Thrombophilia is defined äs an increased tendency
to thrombosis and can be inherited or acquired
(Tablel). The thrombotic events in patients with
inherited thrombophilia tend to occur at a young age,
are often idiopathic, recurrent, follow minimal provo-
cation (e.g. aeroplane flight) and tend to occur at
unusual sites (e.g. inferior vena cava, mesenteric and
cerebral veins).
Venous thrombosis
Venous thromboembolism is the predominant clinical
manifestation of familial thrombophilia. This usually
manifests äs deep vein thrombosis or pulmonary
embolism but venous thrombosis in unusual sites is
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Table l Risk factors for venous thrombosis
Acquired
Age
Previous thrombosis
Surgery
Obesity
Immobihty
Sepsis
Malignancy
Oral contraceptives
Pregnancy
Hormone replacement therapy
Anti-phospholipid syndrome
Myeloproliferative disorders
Nephrotic syndrome
Inhented
Anüthrombm deficiency
Protein C deficiency
Protein S deficiency
APC resistance/Factor V Leiden
Prothrombm 20210A allele
Dysfibnnogenaemia
Homocystmuna
l hrombomodulm defect
Mixed
Hyperhomocystemaemid
High factor VII level
High fibnnogen level
also well recognized. Other presenttng features
include thrombophlebitis, observed more commonly
m association with protein C or protein S deficiency,
the post-phlebitic syndrome, includmg venous ulcera-
tion over the internal maüeolus. Warfann-mduced
skin necrosis and neonatal purpura fulminans are
rare manifestations of familial thrombophiha and
there is recent evidence of an association with
increased risk of fetal loss (Table 2). Although several
studies have shown an association between arterial
disease and familial thrombophilia, specifically factor
V Leiden, the evidence is less clear than for venous
thrombosis and the risk may be restricted to young
individuals. Overall, approximately 55% of individu-
als with anti-thrombm, protein C and protein S defi-
ciency give a history of venous thrombosis and in
80% of these the first thrombotic event occurs before
the age of 40 years [1,2], In individuals with factor V
Leiden, the percentage of those having venous throm-
bosis is lower and the age of onset of the first throm-
botic event later than with the other recognized
causes of familial thrombophilia [1,2], The throm-
botic risk is greatly enhanced in subjects with com-
bined defects and in those who are homozygous for
factor V Leiden. In subjects with deficiencies of anti-
thrombin, protein C or protein S, venous thrombotic
events occur spontaneously in approximately 50%. In
the remainder, other associated risk factors are evi-
dent. These include pregnancy, including the puer-
perium, surgery, oral contraceptive usage and
prolonged periods of immobilization. It has been sug-
gested that spontaneous venous thrombosis is less
common in subjects with factor V Leiden [3].
Desmarais and colleagues [4] found that activated
protein C resistance was a less important risk factor in
unselected patients with pulmonary emboli (PE) and
Manten using the factor V Leiden test found a weak
association in a similar group of patients (relative risk
of 3.3 for PE alone versus 6.9 for deep vein thrombosis
(DVT) alone) [5]. These papers have shown that there
may be subtle differences between risk factors leading
to DVT and those leading to subsequent PE [4,5].
Anti-thrombin deficiency
Since its Identification in 1965, numerous families
with anti-thrombin deficiency have been reported
[6,7] and a large number of causative mutations have
been described [8].
Type I (quantitative defects) and IIRS (reactive site
functional defect) are both associated with throm-
bophilia whilst type II heparin binding site defect
(HBS) is not, at least in the heterozygous form. Anti-
thrombin deficiency appears to be more clinically
severe than deficiencies of protein C and protein S.
The prevalence of anti-thrombin deficiency has been
reported to be 4% amongst thrombophilic patients
[9], 1% in patients presentmg with a first DVT [10]
and 0.02% in blood donors [11]. The 50-fold differ-
ence in the prevalence among patients with a first
event DVT and that in the 'healthy' population of
Table 2 Clmical conditions associated with familial thrombophilia
Venous thrombosis
lower limb
pelvic
mesenteric
cerebral venous
pulmonary embolus
Post-phlebitic syndrome
Leg ulcers
Warfann-mduced skin necrosis
"Neonatal purpura fulminans
Recurrent fetal loss
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blood donors, Supports a higher thrombotic risk than
other familial defects such äs protein C deficiency.
However, such a difference could not be found in a
direct comparison in a population study,[9].
Protein C deficiency
Since its identification in 1981 numerous families
with hereditary protein C deficiency have been
reported [12-14]. Heterozygous deficiency increases
the risk of thrombosis without any clear difference by
type (type l - quantitative defect, type 2 - qualitative
defect) of deficiency or by underlying mutation [l 5].
Family members with protein C deficiency have an
8-10-fold increased risk of venous thrombosis and by
the age of 40, half of them will have experienced at
least one thrombotic event [l 6,17]. This risk is similar
to that observed in a population based study [10].
Protein S deficiency
The association between familial protein S deficiency
and thrombosis was first described in 1984 [18]. At
least 32 causative mutations in the protein S gene
have been reported [1], a relatively small number in
comparison to anti-thrombin and protein C muta-
tions, owing to the complexity of the protein S gene.
Three types of defect are recognized, type I (low
plasma total and free protein S), type II (functional
defect) and type III (low free protein S). Type I and type
III deficiencies have recently been shown to be pheno-
typic variations of the same genotype [19] and many
of the previously described type II defects are now
known to represent activated protein C resistance and
to have been previously misdiagnosed [20]. As the
prevalence of protein S deficiency in the general pop-
ulation and the incidence rate in families is unknown,
so the risk of thrombosis associated with protein S
deficiency has not been quantified.
APC resistance
A single point mutation in the factor V gene
(G1691A, factor V Leiden) [21] accounts for almost
all the cases of true activated protein C resistance
first described by Dahlbäck in 1993 [22], This is the
most frequenl inherited defect associated with
venous thrombosis and has been found in 20% of
consecutive patients with a first DVT [2 3] (Table 3). It
has been found in up to 7% of the healthy European
Table 3 The currently accepted familial prothrombotic disorders,
estimates of their frequencies in the general population, and
among patients presenting with spontaneous venous thrombosis.
(Composite data from [1,2.26] äs well äs unpublished
observations)
Defect
Frequency
in the general
population
Frequency
in patients
with thrombosis
APC resistance/Factor V
Leiden
Prothrombin 2021OA allele
Antithrombin deficiency
Protein C deficiency
Protein S deficiency
Dysfibrinogenaemia
Homocystinuria
Thrombomodulin mutations
1-2%
0.02%
0.2%
0.1%
6%
1%
3%
1-2%
*Caucasian populations
population [24], but its prevalence varies greatly
depending on the ethnic origin of the population
studied [25],
In a family study the risk of thrombosis was higher
among affected relatives and approximately 25% of
those affected had suffered a thrombosis by the age of
50 [24]. Although this risk is lower than that reported
for familial protein C deficiency [17] the difference
may be due to selection bias: because APC resistance
is common, affected patients may not have been äs
highly selected äs families with protein C deficiency in
previous studies. In a population-based control study
the relative risk for APC resistance was 7 whereas for
protein C deficiency it was 6.5 suggesting that the two
abnormalities do not differ in severity [10,26].
Prothrombin 20210 G > A
The most recent genetic factor to be associated with
thrombosis was reported in November 1996 and is
due to a single point mutation at position 20210 of
the prothrombin gene [27]. This variant was
detected in 6.2% of consecutive patients with
thrombosis and in 2.3% of healthy control subjects,
which yields a relative risk of 2.8 for carriers of the
variant versus non-carriers [27]. This implies that it
is a relatively frequent risk factor conferring a
smaller risk than deficiencies of anti-thrombin, pro-
tein C, protein S or factor V Leiden. The 2.3% preva-
lence in the control population was based on 474
healthy subjects, but in a second subsequent sample
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of 500 healthy individuals in Leiden, the incidence
was less than 1% [28] which is similar to that found
in Sheffield, UK (0.6% of blood donors). If the true
prevalence is nearer 1%, this would yield a relative
risk similar to those observed for the other throm-
bophilic factors referred to above. The prothrombin
2021OA variant is closely linked to factor II levels,
which, in turn, are associated with the increased
risk of thrombosis (Table 4).
Other defects
A number of other rare inherited disorders are associ-
ated with venous thromboembolism (Table 1). These
include dysfibrinogenaeinia [29], homocystinuria
due to cystathionine ß-synthase deficiency [30] and
thrombomodulin mutations [31.32].
Other genetic defects such äs deficiencies of plas-
minogen, heparin cofactor II and factor XII [1] have
been suggested to be associated with venous thrombo-
embolism but evidence for a causal relationship is
lacking.
Increased levels of FVIII [33] and homocysteine
[34,35] have been shown to be associated with
venous thrombosis but these levels are strongly influ-
enced by environmental factors and the contribution
of genetic factors is uncertain. Factor VIII levels
exceeding 150IU/dL, found in 11% of the popula-
tion, are associated with a six-fold increase in the risk
of thrombosis [33]. Hyperhomocysteinaemia
(defined äs a level above the 95th percentile: i.e.
exceeding 18.5μηιο1/ί) was found to be associated
with a 2.5-fold increased risk of deep vein thrombosis
[34].
Table 4 Prothrombin levels. prothrombin genotype and risk of
thrombosis
Prevalence of
Plasma
prothrombin
level lU/dL
<95
95-104
104-115
>115
202 10A genotype
Relative
risk (OR)
1
1.3
1.4
2.2
Patients
(%)
0
2.8
6.9
18.2
Controls
(%)
0
0
1.7
9. B
Results for 424 patients and 474 controls for whom DNA was
available and none of whom were on oral anticoagulant therapy
( 2 7 } .
Combined defects
Although combined defects of anti-thrombin, protein
C and protein S deficiency have been reported, they
are extremely rare due to the low allelic frequency of
each of these defects. Factor V Leiden, however, is
fairly common and patients with combinations of this
and anti-thrombin, protein C and S deficiency have
been reported. Homozygous patients with protein C or
S deficiency have a severe phenotype with thrombosis
developing shortly after birth (purpura fulminans).
Patients homozygous for factor V Leiden are more
common and have a thrombotic risk ten times higher
than heterozygous patients [28]. The reports on
patients with combined defects all suggest that the
thrombotic risk is higher than persons with a single
defect [28]. In thrombophilic families with protein C
deficiency and Factor V Leiden, for example, a history
of thrombosis was present in 31% of individuals with
only protein C deficiency, in 13% of those with only
factor V Leiden and in 73% of those with both defects
[36.37,28]. A similar increase in risk was reported in
patients with factor V Leiden combined with
antithrombin deficiency [38] or with protein S defi-
ciency [39].
Risk assessment, oral contraceptives and
pregnancy
In The Netherlands, the estimated incidence of venous
thrombosis among women not taking oral contracep-
tives is 0.8 per 10000 women years [40]. This com-
pares with a Iower estimate of 0.4 per 10000 in a
slightly younger group of women reported from the UK
[41]. In the Dutch study the incidence of DVT rose to
3.0 per 10 000 women years among users of oral con-
traceptives with a further increase to 28.5 per 10 000
women years among oral contraceptive users who also
possessed the factor V (Leiden) mutation. The incidence
of DVT among women with the factor V mutation but
who were not taking oral contraceptives was 5.7 per
10 000 women years. On the assumption that the case
fatality of venous thrombosis among young adults is
2% this would mean that for carriers of the factor V
mutation, the usage of combined oral contraceptives
for 12 months would result in a death rate, from pul-
monary embolism of 5.7 per 100 000. When providing
counselling in respect of the venous thrombotic risk
among oral contraceptive users it is important to appre-
ciate ethnic/geographical differences in the prevalence
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of the factor V mutation. Thus, prevalences of 3%, 6%
and 15% have been reported in The Netherlands, USA
and Southern Sweden, respectively. In contrast,- the
prevalence of the factor V mutation in Asia and Africa
appears to be extremely low. Current data do not point
to an immediate need for widespread screening of
women asking for the oral contraceptive pill.
When providing counselling it is important to
appreciate that, at least in men, a previous venous
thrombosis is a strong risk factor for a further throm-
botic event. Although it remains to be established, it
would be surprising if this did not also pertain to
women.
Venous thromboembolism, including fatal pul-
monary embolism, is an important cause of morbid-
ity and mortality in pregnancy. The pregnancy-
associated thrombotic risk persists for at least 6 weeks
after delivery. Although detailed Information is limi-
ted, the available evidence suggests that the preg-
nancy-associated thrombotic risk is greater in women
with anti-thrombin deficiency than in those with defi-
ciencies of either protein C or protein S [42]. In
Sweden, a diagnosis of APC-R was made in 60% of
women who developed a first episode of venous
thrombosis during pregnancy. Decisions regarding
the use and timing of thromboprophylaxis for preg-
nant women with familial thrombophilia are likely to
be influenced by the nature of the defect and whether
this is present alone or in combination with other
genetic and acquired prothrombotic risk factors.
Consideration should be given to the previous throm-
botic history, particularly in relation to oral contra-
ceptive usage and previous pregnancies. The obstetric
history of other affected family members may also
influence decision-making.
A number of different thromboprophylactic regimes
have been used during pregnancy. Until recently many
favoured the use of heparin in the first and third
trimesters with warfarin being substituted in the sec-
ond trimester. At present, more clinicians are recom-
mending heparin for the entire pregnancy with
conversion to warfarin for a period of approximately 2
months after delivery. Both unfractionated and low
molecular heparins are used, the latter havin,g the
advantage that monitoring is considered unnecessary.
Women with anti-thrombin deficiency appear to be at
a particularly high risk of thrombosis during preg-
nancy and the puerperium and it is worth considering
the use of anti-thrombin concentrate at delivery.
Recent evidence for an increased risk of fetal loss in
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women with familial thrombophilia may also influ-
ence decision-making in respect of anti-coagulant
therapy during pregnancy [43].
Women receiving oral anti-coagulants and con-
templating pregnancy pose a particularly difficult
problem äs the beneficial anti-thrombotic action of
coumarins needs to be weighed against their potential
embryopathic effects. One possible strategy is to dis-
continue the warfarin and substitute heparin.
Although this is undoubtedly beneficial for the foetus,
the prolonged exposure to heparin may be compli-
cated by unacceptable osteoporosis.
Prevention of thrombosis
In the short term, prevention involves avoidance of
risk factors, the use of graduated elastic stockings and
subcutaneous unfractionated or low molecular
weight heparin at times of increased risk. Ultimately
the long-term prevention of thrombosis, apart from
avoidance of high-risk situations, centres around the
use of oral anti-coagulants. The benefit of these
agents has to be balanced against inconvenience, cost
and the risk of bleeding whilst on warfarin. In non-
thrombophilic patients life-long oral anticoagulation
is offered to those with two or more spontaneous
thrombotic events or those with a single life-threaten-
ing thrombotic event. An important question is
whether patients with thrombophilia should be man-
aged differently. It is not possible to make defmite
recommendations at present due to the lack of pub-
lished data.
Management of acute thrombosis
The management of acute thrombosis in a patient
with familial thrombophilia, is usually identical to
that of patients without inherited defects. Unfraction-
ated heparin is infused at 1300 U per hour following
an initial bolus of 5000 U aiming to maintain the
APTT ratio at l. 5-2.5. Warfarin is commenced on the
first day of heparin treatment. In view of the risk of
warfarin-induced skin necrosis (see later) a smaller
loading dose, than the usual 10mg daily, is given in
protein C and S deficient patients. Heparin is given for
at least 5 day s or until the INR is >2.0. The thera-
peutic ränge for first thrombotic events is around
2.0-3.0.
Rarely, patients with anti-thrombin deficiency
require very high doses of heparin to achieve ade-
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quate anti-coagulation. a phenomenon known äs
heparin resistance. Although an anti-thrombin con-
centrate is available, its value has not been assessed in
randomized trials. It is reasonable to use the concen-
trate where adequate anti-coagulation can not be
achieved with heparin alone or where there is clinical
extension or recurrence despite adequate anti-
coagulation.
Patients with familial thrombophilia and a first
thrombosis should be anti-coagulated for 6 months
using a therapeutic ratio of around 2.0-3.0. In non-
thrombophilic patients, 6 months anti-coagulation
has been shown to be superior to 6 weeks [44]. This.
together with the fact that thrombophilia is a perma-
nent risk factor suggests that at present 6 months
should be the optimal anti-coagulation of these
patients. For patients with more than one thrombosis,
life-long anti-coagulation should be offered. Recently
Shulman and colleagues have shown that long-term
anti-coagulation is more effective in reducing the risk
of recurrence after two events than short-term treat-
ment [45].
Purpurn fulminans
Neonatal purpura fulminans is characterized by the
development of skin and systemic thrombosis in
neonates due to homozygous or compound heterozy-
gous protein C or protein S deficiency. Although fresh
frozen plasma has been used successfully to treat this
condition, the current treatment of choice is protein C
concentrate which is virally inactivated and has the
additional advantage of being available at a high con-
centration [46].
Warfarin-induced skin necrosis
A rare complication of warfarin therapy is skin necro-
sis that occurs soon after initiation of therapy with
this agent. It has been described in protein C defi-
ciency, which accounts for a third of all reported cases
[47], in protein S deficiency [48] and in activated pro-
tein C resistance [49]. Warfarin-induced skin necrosis
(WISN) classically occurs in the first week after war-
farin initiation, more commonly affects females and
involves the fatty parts of the body such äs the thighs
and breast. WISN is believed to be due to the more
rapid fall in plasma concentrations of the vitamin K-
dependent, naturally occurring anti-coagulants (pro-
tein C and S) compared to the fall in the levels of
factors II, VII, IX and X. This temporary dissociation
results in a hypercoagulable state which leads to
thrombosis of the dermis and subcutaneous fat. It can
be prevented by the use of smaller loading doses of
warfarin which initially produce slower anti-coagula-
tion, and by the use of concomitant heparin therapy
at the time of warfarin initiation. Protein C concen-
trate is available and has been used in established
WISN associated with protein C deficiency [50].
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